OMOlesya Nikolayevna Mazko

Olesya Nikolayevna Mazko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olesya Nikolayevna Mazko has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AN INVESTIGATION INTO THE TOXIC EFFECTS OF A DIETARY SUPPLEMENT MADE FROM LION'S MANE MUSHROOM FOLLOWING A ONE-TIME DOSE

    by Olesya N. Mazko, Olesya G. Petrova, Mikhail S. Kapran

    Introduction. The quest for neuroprotective agents has become increasingly critical due to the rising prevalence of neurodegenerative diseases linked to an aging demographic. A multi-faceted formulation has been created, incorporating Hericium erinaceus biomass, extracts from Eleutherococcus senticosus and Camellia sinensis, B vitamins, and succinic acid, which operates through multitarget mechanisms. Objective. This study aimed to assess the toxicometric characteristics of the formulation following a single oral dose administration. Materials and Methods. The study focused on the composition (H. erinaceus mycelium and fruiting body – 250 mg; extracts of Eleutherococcus and green tea – 100 mg each; succinic acid – 100 mg; vitamins B6 and B2 – 5 mg each; inositol – 1 mg; folic acid – 0.4 mg). The experiment was carried out on outbred Wistar rats of both genders (weight range 210–256 g) in accordance with OECD Guideline No. 423. Three experimental groups were established (doses of 500, 2000, and 5000 mg/kg) along with an intact control group (n = 10 per group). Observations were made over a 14-day period, monitoring mortality, clinical signs, behavioral changes, body weight fluctuations, and blood biochemistry parameters (ALT, AST, glucose, bilirubin, creatinine, urea, and lipids). Results. No fatalities were observed in any of the groups. Behavioral modifications were restricted to a temporary rise in locomotor activity. There were no indications of acute intoxication. Based on K.K. Sidorov's classification, an LD50 greater than 5000 mg/kg is categorized as hazard class IV, which includes "Low-toxic substances". No statistically significant alterations in liver cytolysis markers (ALT, AST) or indicators of the hepatobiliary system (bilirubin) were found. A hypoglycemic effect was noted, with glucose levels decreasing to 3.45–3.30 mmol/L at doses of 2000 and 5000 mg/kg (p < 0.001), alongside a moderate reduction in creatinine and fluctuations in urea levels, all without evidence of nephrotoxicity. Conclusion. A single intragastric administration of the formulation at doses up to 5000 mg/kg classifies it as a low-toxicity compound (LD50>5000 mg/kg). The formulation was considered safe for subsequent extended preclinical trials aimed at evaluating specific neuroprotective and immunomodulatory effects, and it also holds potential as a metabolic corrector for carbohydrate metabolism.

  • INNOVATIVE BIOMEDICAL TECHNIQUES UTILIZING MATERIALS DERIVED FROM BACTERIAL СELLULOSE AND CRYOPRECIPITATED BLOOD PLASMA AS HERNIOPROSTHESES IN THE SIMULATION OF ANTERIOR ABDOMINAL WALL HERNIAS

    by Andrey N. Zharikov, Aleksandr R. Aliev, Vasily V. Seroshtanov, Olesya N. Mazko, Olesya G. Petrova, Natalya M. Semenikhina, Andrey P. Momot

    Introduction. Currently, herniology is exploring new composite materials that possess skeletal properties to reinforce hernial defects while also exhibiting anti-adhesive qualities, thereby preventing the fusion of underlying organs with the hernioprosthesis. Objective. This study aims to conduct a comparative analysis of prosthetic techniques for acute muscular-aponeurotic defects in the anterior abdominal wall of rabbits, utilizing bacterial cellulose and animal autocryoprecipitate in experimental procedures. Materials and Methods. We conducted a study on the prosthetics of acute muscular-aponeurotic defects in the anterior abdominal wall (AAW) in three groups of rabbits. The prosthetic materials used in the study included: Group 1 (n=10) – bacterial cellulose (BC), Group 2 (n=10) – traditional polypropylene mesh (PPM), and Group 3 (n=10) – polypropylene mesh augmented with animal autocryoprecipitate. The implantation period lasted between 45 to 60 days, after which samples were collected for morphological examination. The effectiveness of the prosthetic materials and their potential toxicity were monitored through ultrasound scanning of the AAW and routine blood tests. Results. During the implantation of materials derived from PPM, significant fibrotic changes in the AAW were observed, along with adhesions to underlying tissues, which were confirmed through ultrasound examinations and relaparotomy (S=34.6%). When BC was applied after 60 days, the material had formed a capsule, and the area of adhesion to the intestinal loops was minimal (S=11.3%). Additionally, the reinforced properties of the AAW were maintained. When PPM was combined with animal-derived autocryoprecipitate, adhesion formations were still present, but these were considerably less significant compared to those seen with PPM alone (S=24.8%). Morphological studies confirmed a substantial response in connective tissue formation when using PPM and autocryoprecipitate in animals, while the effect was less pronounced with the application of BC. Importantly, there were no toxic reactions or significant alterations noted in blood tests throughout the study. As a result of this research, a new experimental hybrid composite material with anti-adhesion properties has been developed, combining PPM and BC. Conclusion. For the first time, experimental biomedical technologies for prosthetics of acute muscular-aponeurotic defects of AAW have been created using new materials, including BC, a fibrin composite obtained from animal autocryoprecipitate, and a dry hybrid composite based on BC and PPM. The best anti-adhesive effectiveness of BC has been experimentally proven, both when used as an independent material and in hybrid composites for prosthetic hernioplasty on models of hernias of the anterior abdominal wall.

  • Results of the survey of dentists of the constituent entities of the Russian Federation on the topic of Xerostomia

    by O.E. Shishkina, O.N. Mazko, O.V. Shoykhet, N.V. Semennikova, E.A. Berent, A.A. Fedorov

    The article presents the results of a survey of dentists of different specialties on xerostomia, as well as an analysis of diagnostic approaches and treatment tactics used in dental departments of outpatient clinics for diagnostics and treatment tactics used in dental departments of outpatient clinics when curating patients with complaints of dry mouth. In addition, an attempt was made to assess the current state of the market for drugs for the symptomatic treatment of dry mouth syndrome in the Russian Federation based on prescription data provided by specialist doctors. 1,809 dentists took part in the survey. It was found that general dentists and dentists with more than 10 years of experience in practical medicine more often encounter patients suffering from xerostomia. Most patients with xerostomia seen at a dental appointment are women (82%) over 60 years of age with concomitant pathology of the endocrine and cardiovascular systems. Men with symptoms of xerostomia are seen in the practice of specialist doctors mainly with diseases of the endocrine system. Slightly less than half of the surveyed doctors (48%) refer their patients to more experienced specialists, only 41% of doctors prescribe special moisturizing agents to correct the symptoms of dry mouth. 70% of doctors of various specialties believe that there are not enough drugs for symptomatic therapy of xerostomia on the Russian market. When prescribing salivary substitutes, doctors prefer foreign-made drugs.

  • Hydrating dental gel for symptomatic treatment of xerostomia: requirements and research design

    by Valentina M. Vorobyova, Olesya Nikolaevna Mazko, Oksana Evgenievna Shishkina, Svetlana Ivanovna Tokmakova, Evgeny Vladimirovich Mokrenko

    Xerostomia (dry mouth) is a common syndrome with multiple causes that tends to increase in prevalence as the population ages. The imitation of physiological saliva is a modern concept in the development of saliva replacement agents, with the gel dose form being considered optimal. This article provides a scientific rationale for the requirements and design of the pharmaceutical development of a hydrating dental gel for the symptomatic treatment of xerostomia in the context of import substitution. The information-retrieval stage of pharmaceutical development of artificial saliva is based on an understanding of the pathophysiology and etiology of xerostomia, as well as modern treatment approaches and knowledge of the composition, properties, and biological functions of human physiological saliva. The research stage of pharmaceutical development includes identifying potential molecules and compounds capable of mimicking the properties and functions of saliva, as well as formulating and improving the gel composition. An essential aspect is selecting a polymer combination with mucoadhesive properties. The search for a polymer composition includes cellulose derivatives, acrylic acid copolymers, alginates, hyaluronates, pectins, carrageenans, and fucoidans. Further expansion of structure-forming mucoadhesive polymers is possible through the use of recombinant mucins obtained by genetic engineering and plant extracts rich in polysaccharides that mimic mucin properties. Lysozyme, peroxidase, and lactoferrin, which are currently produced as bulk substances, as well as plant extracts, provide antimicrobial effects of artificial saliva. Buffering properties are maintained by potassium, sodium, and calcium bicarbonates and phosphates. Calcium lactate and fluorides impart remineralizing properties. The formulation of saliva substitutes includes organoleptic corrigents and preservatives. Selection criteria for compositions include quality parameters, biopharmaceutical performance, and antimicrobial and antioxidant characteristics of the saliva substitute. The proposed packaging for the hydrating dental gel includes 10–30 mL tubes, single-use stick packs, or strip packaging. The standardization stage involves modifying and validating analytical procedures specific to the composition, conducting stability tests, determining shelf life, and developing the process flowchart and regulatory documentation drafts. The composition and functions of salivary gland secretions serve as the foundation for defining the requirements and characteristics of the hydrating dental gel intended for pharmaceutical development. The optimal formulation is sought among combinations of mucoadhesive polymers with compounds exhibiting antimicrobial and remineralizing activity. Scientific data were analyzed and organized into a unified design framework for the pharmaceutical development of a hydrating dental gel for xerostomia therapy, comprising information-retrieval, research, and standardization stages. This design framework can be applied in research laboratories and educational institutions to train pharmaceutical industry professionals.

  • Open Access

    Prospects of bacterial cellulose application in dentistry (review of foreign literature)

    by Yu.V. Lunitsyna, L.G. Dvornikova, O.N. Mazko, A.O. Shevyakina, O.V. Bondarenko, S.I. Tokmakova, Ю.в. Луницына

    The article provides an overview of modern literature sources on bacterial cellulose, which, being a natural biopolymer, has unique physico-chemical properties such as high purity, excellent mechanical strength and biocompatibility, absorbent properties, which makes it in demand in various fields of medicine: as wound coatings, in tissue engineering and transplantation, etc. In dentistry, bacterial cellulose manifests itself in several ways. In periodontics, it is used to regenerate gum tissue and bone structures. In endodontics, to preserve the viability of the pulp, to create effective absorbers and sillers. In implantology, bacterial cellulose can be applied during sinus lifting surgery. It is also effective in the treatment of diseases of the oral mucosa due to its barrier and protective properties, contributing to the healing of ulcers and erosions. Conclusion. The article highlights the potential and prospects for the development of dental products and preparations based on bacterial cellulose.


  • Изучение токсичности трипептида Leu-Ile-Lys при однократном введении грызунам

    by Александр Юрьевич Жариков, Артем Сергеевич Кальницкий, Игорь Петрович Бобров, Олеся Николаевна Мазко, Ганна Викторовна Жарикова, Екатерина Олеговна Назарова, Анастасия Евгеньевна Колесникова, Юлия Артемовна Антонова, Ангелина Олеговна Гильмиярова

    Проведено изучение токсичности трипептида Leu-Ile-Lys при однократном внутрижелудочном введении в дозе 2000 мг/кг мышам и крысам (самцы и самки поровну). Введение Leu-Ile-Lys мышам и крысам в дозе 2000 мг/кг не вызвало гибели животных, а также проявлений токсичности. Масса тела экспериментальных животных не имела статистически значимых межгрупповых различий. При патоморфологическом исследовании внутренних органов каких-либо патологических изменений обнаружено не было. Таким образом, трипептид Leu-Ile-Lys относится к IV классу опасности (малоопасные вещества). Полученные данные свидетельствуют о перспективе клинического применения указанного соединения.

  • Open Access

    AN EXPERIMENTAL STUDY ON USING BACTERIAL CELLULOSE GRAFTS TO REPAIR ACUTE ABDOMINAL WALL DEFECTS

    by Andrey N. Zharikov, Andrey P. Momot, Alexander R. Aliev, Vasily V. Seroshtanov, Olesya N. Mazko, Olesya G. Petrova, Natalya M. Semenikhina

    Introduction. The surgical management of anterior abdominal wall hernias remains a significant challenge, driving the continued pursuit of an ideal prosthetic material that is biocompatible, durable, and resistant to infection. While synthetic polypropylene meshes are widely used, they are associated with long-term complications such as chronic inflammation and adhesion formation. Consequently, research interest has shifted towards biological prostheses. This study investigates a promising biopolymer derived from bacterial cellulose (BC) as a novel alternative for hernia repair. Objective. This study aimed to evaluate the feasibility and in vivo tissue response following the experimental implantation of a bacterial cellulose-based prosthesis for the closure of acute musculoaponeurotic defects in the anterior abdominal wall. Materials and Methods. A preclinical study was conducted using five rabbit models. An acute musculoaponeurotic defect was surgically created and repaired using a wet BC plate implanted via the sublay technique. The implant was left in situ for 60 days. Postoperative assessment included clinical evaluation of the surgical site, followed by explant analysis. This involved tensile strength testing (tensometry), comprehensive histopathological examination (pathomorphology), and detailed morphometric analysis. Results. At the 60-day explantation, no signs of infection, inflammation, or hernia recurrence were observed. The BC implant demonstrated full integration, achieving firm fixation to the defect margins and complete encapsulation within a well-defined fibrous capsule. Critically, no adhesions were found between the implant site and the underlying intestinal loops. Tensile testing confirmed the mechanical integrity of the explanted material, with no evidence of rupture. Histological analysis revealed that the BC had undergone significant consolidation, losing its fluid component and transforming into a thickened, dense, white elliptical structure approximately 1 cm in width. Conclusion. The findings indicate that bacterial cellulose is a highly promising biomaterial for prosthetic reinforcement of acute abdominal wall defects. Its high biocompatibility, mechanical resilience, and ability to integrate without inducing adhesions support its potential for further development in clinical hernia repair applications.

  • Effect of the tripeptide Leu-Ile-Lys on the gastric mucosa in an experiment

    by A.YU. Zharikov, О.N. Mazko, I.P. Bobrov, А.S. Kalnitsky, S.N. Nurzai, G.V. Zharikova, E.O. Nazarova, K.S. Rudenko

    Introduction. The high prevalence of gastric ulcer, as well as its multiple etiologies substantiate the urgency of developing new drugs effective in this condition. Previously, the antiulcer effect of the tripeptide Leu-Ile-Lys (LK-3) was revealed under experimental conditions in gastropathies of various origins. To clarify the mechanism of action of this compound, an in-depth experimental study of its effects on the gastric mucosa (GM) is necessary. Aim. To study the effect of the tripeptide LK-3 on GM under experimental conditions. Materials and methods. The experiment was performed on 16 Wistar rats. All animals were divided into two groups: the intact group and the group with intragastric administration of the tripeptide LK-3 (for 7 days, 11,5 mg/kg). Pathomorphological examination of the stomachs of experimental rats was performed. A histological picture of the GM was examined, and its thickness was measured. In addition, the density and composition of the inflammatory infiltrate, as well as the DNA replication index in the nuclei of cervical GM cells were determined. Results. During gross and microscopic examination, no pathological changes in the GM were revealed in either experimental group. The tripeptide LK-3 administration caused a statistically significant increase in GM thickness, by 1,4 times, compared to the intact group. In addition, the DNA replication ratio in cervical GM cells in rats treated with LK-3 was 1,2 times higher than in intact animals. At the same time, 100% of the cells studied were in the S-phase of the cell cycle after administration of LK-3, compared to 75% in the intact group. Conclusion. A 7-day intragastric administration of the tripeptide LK-3 (11,5 mg/kg) to rats caused an increase in GM thickness and in the proportion of cells in the S-phase of the cell cycle.

  • Open Access

    EFFECT OF LEU-ILE-LYS TRIPEPTIDE ON EXPERIMENTAL HISTAMINE-INDUCED GASTROPATHY

    by Alexander Yu. Zharikov, Olesya N. Mazko, Igor P. Bobrov, Artem S. Kalnitsky, Ganna V. Zharikova

    Introduction. The high prevalence of gastric ulcer, a polyethological disease formed due to increased hydrochloric acid and/or violation of protective properties of the gastric mucosa, determines the urgency of developing new drugs with an anticarcinogenic effect. According to the results of research conducted at the Altai State Medical University, the tripeptide Leu-Ile-Lys was obtained, which was successfully tested under experimental conditions against the background of gastropathies caused by the administration of drugs that directly or indirectly reduce the protective properties of the gastric mucosa. In the next stage of the preclinical study of the anti-ulcer properties of this compound, it is necessary to test it against the background of gastropathy induced by the administration of histamine, a substance that stimulates the gastric secretion of hydrochloric acid. Objective. To study the effect of the Leu-Ile-Lys tripeptide on the course of experimental histamine-induced gastropathy. Materials and Methods. Stock Wistar rats were used as a biological model for the study. The animals were divided into the control group, the Leu-Ile-Lys tripeptide administration group (11.5 mg/kg) and the omeprazole comparison drug administration group (37 mg/kg). These substances were administered intragastrically for 7 days. Histamine-induced gastropathy was simulated in animals of all groups. Subsequently, the stomachs of experimental rats were extracted to study the pathomorphological signs of the pathology. Results. When histamine-induced gastropathy in the control group, broad surface erosions of the gastric mucosa were revealed, as well as dystrophy and necrobiosis of the integumentary pit epithelium with the development of lymphoplasmocytic infiltration. Against this background, with the administration of Leu-Ile-Lys tripeptide and omeprazole, the morphological picture of the gastric mucosa was close to normal. In the Leu-Ile-Lys tripeptide group, the thickness of the gastric mucosa increased statistically significantly by 1.1 times relative to the control, while in the indicator omeprazole group, the value studied indicator was statistically significantly lower than in the Leu-Ile-Lys tripeptide group by 1.3 times, and in untreated rats by 1.2 times. Conclusion. Thus, the Leu-Ile-Lys tripeptide demonstrated an anti-ulcerative effect against the background of histamine-induced gastropathy, which was accompanied by an increase in the thickness of the gastric mucosa relative to disease control and the omeprazole administration group.

  • EVALUATION OF THE EFFICACY OF LEU-ILE-LYS TRIPEPTIDE IN THE CONTEXT OF CHRONIC ACETATE-INDUCED GASTROPATHY

    by Alexander Yu. Zharikov, Olesya N. Mazko, Igor P. Bobrov, Artem S. Kalnitsky, Ganna V. Zharikova, Anastasia E. Kolesnikova, Ekaterina O. Nazarova, Yulia A. Antonova, Anna A. Skokova

    Introduction. Peptic ulcer is a common multifactorial disease that significantly reduces the quality of life of a large number of patients. An obligatory stage in the development of new methods of pharmacological correction of this pathology is their experimental testing on models of acute and chronic gastropathy. Previously, studies were conducted on the basis of the Altai State Medical University, which demonstrated the Leu-Ile-Lys antiulcer effect of the tripeptide on models of acute gastropathy: indomethacin, ethanol and predniolone. For a complete preclinical assessment of the test substance, it is necessary to test it under conditions of modeling chronic gastric ulceration modeling. Objective. Study of the effect of Leu-Ile-Lys tripeptide on the course of experimental chronic "acetate" gastropathy. Materials and methods. The experiments were carried out on stock Wistar rats, divided into a disease control group, a treatment group that received Leu-Ile-Lys tripeptide at a dose of 11.5 mg / kg and a comparison group administered omeprazole at a dose of 37 mg/kg. In all groups, chronic acetate gastropathy was simulated, followed by intragastric administration of the studied substances for 5 days. At the end of the experiment, the stomachs of the experimental animals were extracted, revealing macro- and microscopic signs of the development of the pathological process. Results. The size of ulcerative defects compared to the same indicator of the disease control group was significantly decreased by 2.5 times in rats treated with the Leu-Ile-Lys tripeptide, while against the background of omeprazole administration it decreased by 1.7 times. According to the results of a pathohistological study in the Leu-Ile-Lys tripeptide treatment group, a decrease in inflammatory infiltration was recorded in the area of ulcerative defects, an increase in the number of collagen fibers and an increase in angiogenesis processes relative to the disease control groups and the administration of omeprazole. Conclusion. Thus, during the experimental testing of the Leu-Ile-Lys tripeptide against the background of chronic "acetate" gastropathy, the presence of an antiulcer effect of the substance under study was revealed, which is characterized by a decrease in the size of ulcerative defects, as well as activation of regeneration processes.